---
title: "Immunic, Inc. (IMUX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IMUX.US.md"
symbol: "IMUX.US"
name: "Immunic, Inc."
industry: "Biotechnology"
datetime: "2026-04-16T19:30:06.557Z"
locales:
  - [en](https://longbridge.com/en/quote/IMUX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IMUX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IMUX.US.md)
---

# Immunic, Inc. (IMUX.US)

## Company Overview

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [imux.com](https://imux.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.49 | 223 | - | - | - |
| PB | -21.70 | 545 | 7.59 | 5.56 | 2.44 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-15T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 89% |
| Hold | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.02 |
| Highest Target | 10.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IMUX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IMUX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IMUX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IMUX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**